@article {7092,
	title = {Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG)},
	journal = {Clinical Genitourinary Cancer},
	volume = {14},
	year = {2016},
	note = {Export Date: 18 February 2017References: Karim-Kos, H.E., De Vries, E., Soerjomataram, I., Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s (2008) Eur J Cancer, 44, pp. 1345-1389;Sternberg, C., Yagoda, A., Scher, H.I., Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium (1985) J Urol, 133, pp. 403-407; 
Sternberg, C., Yakoda, A., Scher, H.I., M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium (1988) J Urol, 139, pp. 461-469; 
Saxman, S.B., Propert, K.J., Einhorn, L.H., Long-term follow-up of a phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study (1997) J Clin Oncol, 15, pp. 2564-2569; 
Von Der Maase, H., Hansen, S.W., Roberts, J.T., Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study (2000) J Clin Oncol, 18, pp. 3068-3077; 
Bamias, A., Aravantinos, G., Deliveliotis, C., Docetaxel and Cisplatin with granulocyte-colony stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomised, phase III study conducted by the Hellenic Cooperative Oncology Group (2004) J Clin Oncol, 22, pp. 220-228; 
Bajorin, D.F., Dodd, P.M., Mazudmar, M., Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of treatment (1999) J Clin Oncol, 17, pp. 3173-3181; 
Sternberg, C.N., Mulder, P.H.M., Schornagel, J.H., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924 (2001) J Clin Oncol, 19, pp. 2638-2646; 
Sternberg, C.N., De Mulder, P., Schorn, J.H., Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (2006) Eur J Cancer, 42, pp. 50-54; 
Bamias, A., Tiliakos, I., Karali, M.D., Systemic chemotherapy in inoperable or metastatic bladder cancer (2006) Ann Oncol, 17, pp. 553-561; 
Dash, A., Galsky, M.D., Vickers, A.J., Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder (2006) Cancer, 107, pp. 506-513; 
Galsky, M.D., Hahn, N., Rosenberg, J., Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy (2011) J Clin Oncol, 29, pp. 2432-2438; 
Linardou, H., Aravantinos, G., Efstathiou, E., Gemcitabine and carboplatin combination as first-line treatment in elderly and unfit for cisplatin-based chemotherapy patients with advanced bladder carcinoma. A phase II study of the Hellenic Co-operative Oncology Group (2004) Urology, 64, pp. 479-484; 
Bamias, A., Lainakis, G., Kastritis, E., Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy. Report of efficacy, quality of life and geriatric assessment (2007) Oncology, 73, pp. 290-297; 
Karadimou, A., Lianos, E., Pectasides, D., Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: A retrospective analysis (2010) Open Access J Urol, 2, pp. 193-199; 
Kentikelenis, A., Karanikolos, M., Reeves, A., Greece{\textquoteright}s health crisis: From austerity to denialism (2014) Lancet, 383, pp. 748-753; 
Bellmunt, J., Orsola, J., Leow, J., Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up (2014) Ann Oncol, 25, pp. iii40-iii48; 
Cathomas, R., De Santis, M., Galsky, M.D., First-line treatment of metastatic disease: Cisplatin-ineligible patients (2015) Hematol Oncol Clin North Am, 29, pp. 329-340; 
Fedeli, U., Sa, F., Ward, E.M., Treatment of muscle invasive bladder cancer: Evidence from the National Cancer Database, 2003 to 2007 (2011) J Urol, 185, pp. 72-78; 
Witjes, C., Guidelines on Muscle-invasive and Metastatic Bladder Cancer, , http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/, Accessed: April 11, 2015; 
Bamias, A., Efstathiou, E., Moulopoulos Lia, A., The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy (2005) Ann Oncol, 16, pp. 307-313; 
Hurria, A., Cirrincione, C.T., Muss, H.B., Implementing a geriatric assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401 (2011) J Clin Oncol, 29, pp. 1290-1296
},
	month = {2016},
	pages = {e153 - e159},
	abstract = {Background Advanced urothelial cancer (AUCa) is associated with poor long-term survival. Two major concerns are related to nonexposure to cisplatin-based chemotherapy and poor outcome after relapse. Our purpose was to record patterns of practice in AUCa in Greece, focusing on first-line treatment and management of relapsed disease. Methods Patients with AUCa treated from 2011 to 2013 were included in the analysis. Fitness for cisplatin was assessed by recently established criteria. Results Of 327 patients treated with first-line chemotherapy, 179 (55\%) did not receive cisplatin. Criteria for unfitness for cisplatin were: Eastern Cooperative Oncology Group (ECOG) performance status (PS) >= 2, 21\%; creatinine clearance <= 60 mL/min, 55\%; hearing impairment, 8\%; neuropathy, 1\%; and cardiac failure, 5\%. Forty-six patients (27\%) did not fulfill any criterion for unfitness for cisplatin. The main reasons for these deviations were comorbidities (28\%) and advanced age (32\%). Seventy-four (68\%) of 109 patients who experienced a relapse received second-line chemotherapy. The most frequent reason for not offering second-line chemotherapy was poor PS or limited life expectancy (66\%). Conclusion In line with international data, approximately 50\% of Greek patients with AUCa do not receive cisplatin-based chemotherapy, although 27\% of them were suitable for such treatment. In addition, about one third of patients with relapse did not receive second-line chemotherapy because of poor PS or short life expectancy. Enforcing criteria for fitness for cisplatin and earlier diagnosis of relapse represent 2 targets for improvement in current treatment practice for AUCa. {\textcopyright} 2016 Elsevier Inc.},
	keywords = {Advanced urothelial cancer, Fitness for cisplatin, Patterns of practice},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960353120\&doi=10.1016\%2fj.clgc.2015.09.009\&partnerID=40\&md5=7dcd4f5de5c7f1edb7d8e02e2516be07},
	author = {Bamias, A. and Peroukidis, S. and Stamatopoulou, S. and Tzannis, K. and Koutsoukos, K. and Andreadis, C. and Bozionelou, V. and Pistalmatzian, N. and Papatsoris, A. and Stravodimos, K. and Varthalitis, I. and Karamouzis, M. and Milaki, G. and Agorastos, A. and Kentepozidis, N. and Androulakis, N. and Bompolaki, I. and Kalofonos, H. and Mavroudis, D. and Dimopoulos, M.A.}
}
